4-(9-cyclopentyl-5,8-dimethyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-N-(1-methyl-piperidin-4-yl)-benzamide | 1137206-58-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-(9-cyclopentyl-5,8-dimethyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-N-(1-methyl-piperidin-4-yl)-benzamide
• 英文别名: 4-[(9-cyclopentyl-5,8-dimethyl-6-oxo-7,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl)amino]-N-(1-methylpiperidin-4-yl)benzamide
• CAS: 1137206-58-6
• 化学式: C₂₇H₃₇N₇O₂
• 分子量: 491.636
• InChiKey: PAYWLYCXSNGAQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  36
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  93.7
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• [EN] PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE COMME INHIBITEURS DE PROTÉINE KINASES
  申请人：CYCLACEL LTD

  公开号：WO2009040556A1

  公开（公告）日：2009-04-02

  The present invention relates to a compound of formula (VII)I, or a pharmaceutically acceptable salt or ester thereof, wherein: X is NR7; Y is O or N-(CH2)nR19; n is 1, 2 or 3; m is 1 or 2; R1 and R2 are each independently H, alkyl or cycloalkyl; R4 and R4' are each independently H or alkyl; or R4 and R4' together form a spiro cycloalkyl group; R19 is H, alkyl, aryl or a cycloalkyl group; R6 is OR8 or halogen; and R7 and R8 are each independently H or alkyl. Further aspects relate to pharmaceutical compositions comprising said compounds and use therefore in the treatment of proliferative disorders and the like.

  本发明涉及公式(VII)I的化合物，或其药学上可接受的盐或酯，其中：X为NR7；Y为O或N-(CH2)nR19；n为1、2或3；m为1或2；R1和R2分别独立地为H、烷基或环烷基；R4和R4'分别独立地为H或烷基；或者R4和R4'一起形成螺环烷基基团；R19为H、烷基、芳基或环烷基基团；R6为OR8或卤素；而R7和R8各自独立地为H或烷基。进一步方面涉及包括上述化合物的药物组合物以及其在治疗增殖性疾病等方面的用途。
• PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
  申请人：Hollick Jonathan James

  公开号：US20110046093A1

  公开（公告）日：2011-02-24

  The present invention relates to a compound of formula (VII)I, or a pharmaceutically acceptable salt or ester thereof, wherein: X is NR 7 ; Y is O or N—(CH 2 ) n R 19 ; n is 1, 2 or 3; m is 1 or 2; R 1 and R 2 are each independently H, alkyl or cycloalkyl; R 4 and R 4′ each independently H alkyl; or R 4 and R 4′ together form a spiro cycloalkyl group; R 19 is H, alkyl, aryl or a cycloalkyl group; R 6 is OR 8 or halogen; and R 7 and R 8 are each independently H or alkyl. Further aspects relate to pharmaceutical compositions comprising said compounds and use therefore in the treatment of proliferative disorders and the like.

  本发明涉及一种化合物，其化学式为(VII)I，或其药学上可接受的盐或酯，其中：X为NR7；Y为O或N-(CH2)nR19；n为1、2或3；m为1或2；R1和R2各自独立地为H、烷基或环烷基；R4和R4′各自独立地为H烷基；或R4和R4′共同形成一个螺环烷基；R19为H、烷基、芳基或环烷基；R6为OR8或卤素；R7和R8各自独立地为H或烷基。此外，该发明还涉及包含上述化合物的制药组合物以及其在治疗增生性疾病等方面的用途。
• Pyrimidine derivatives as protein kinase inhibitors
  申请人：Cyclacel Limited

  公开号：EP2610256A1

  公开（公告）日：2013-07-03

  The present invention relates to 6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepine derivatives. Further aspects relate to pharmaceutical compositions comprising said compounds and use therefore in the treatment of proliferative disorders and the like.

  本发明涉及 6-氧代-6,7,8,9-四氢-5H-嘧啶并[4,5-b][1,4]二氮杂卓衍生物。此外，本发明还涉及包含上述化合物的药物组合物，以及这些组合物在治疗增殖性疾病等方面的用途。
• US8563542B2
  申请人：——

  公开号：US8563542B2

  公开（公告）日：2013-10-22
• US9133199B2
  申请人：——

  公开号：US9133199B2

  公开（公告）日：2015-09-15